Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Nieves Martinez ChanzaBrandon BernardPhilippe BarthelemyAnna AccarainMarianne PaesmansLaurence DesmyterDaphne T'Kint de RoodenbekeThierry GilSpyridon SiderisThierry RoumeguereAnis A HamidChristopher J SweeneyPublished in: Prostate cancer and prostatic diseases (2021)
While tBRCAm seems to be associated with greater relapse risk in localized disease, tBRCAm did not influence the clinical outcomes of patients presenting with de novo metastatic HSPC treated with conventional therapies. tBRCAm may exert different prognostic effects across the clinical spectrum of prostate cancer.